Nutrition & DietPress Release

Experimental compound raises energy burn in obese mice while sparing muscle

A UC Berkeley compound, TOFA, raised energy expenditure up to 18% in mice and sparing lean mass, and boosted GLP-1 drug effects. Human data are absent.

Saturday, November 21, 2026 0 views
Published in ScienceDaily Nutrition
Article visualization: Experimental compound raises energy burn in obese mice while sparing muscle

Summary

Researchers at UC Berkeley report that an experimental molecule, 5-tetradecyloxy-2-furoic acid (TOFA), increases how much energy the body burns instead of reducing appetite the way GLP-1 drugs such as Ozempic and Wegovy do. In obese mice, it raised energy expenditure by up to 18% without added physical activity or higher body temperature. The animals also showed better blood sugar control, lower harmful blood fats, less liver fat, and fat loss without a significant drop in lean mass. Combined with GLP-1 medication, the effects were greater than either treatment alone. This matters for aging because muscle loss during weight loss can contribute to weakness and frailty. The work was published in Science Advances. It is mouse data only, and safety and effectiveness in people have not been established.

0:00--:--

Detailed Summary

Weight-loss drugs like Ozempic, Wegovy, Mounjaro and Zepbound have changed obesity care, but they work mostly by cutting appetite and food intake. That can bring nausea, poor nutrition and loss of muscle mass, which over time may contribute to weakness and frailty. For readers focused on healthspan, preserving lean tissue while losing fat is a central concern.

Researchers at UC Berkeley, led by Anders Näär, tested a different lever: raising energy expenditure. They studied TOFA, a molecule that interferes with lipid production. In mice, it increased energy expenditure by up to 18%, even though the animals did not become more active and their body temperature did not rise. Obese mice improved blood sugar regulation, had lower harmful blood fats and less liver fat, and lost fat without a significant reduction in lean muscle mass.

The team also combined TOFA with GLP-1 medications. The combination produced greater benefits than either treatment alone, suggesting the two approaches act through complementary routes: one on intake, the other on expenditure. The results were published in Science Advances and point toward possible strategies for obesity, diabetes and fatty liver disease.

The practical implications are limited for now. This is a preclinical mechanism signal, not a treatment. Nothing here supports using TOFA, and the compound is experimental. It is worth watching as an example of how future metabolic therapy might separate fat loss from muscle loss, a distinction that matters for functional capacity in aging.

The caveats are substantial. The findings come from mice, and the article reports effectiveness and safety have not been established in humans. The excerpt does not give group sizes, dosing, duration, or the detailed molecular mechanism, and it does not report muscle strength or function, only lean mass. No lifespan data are mentioned. Readers should check the Science Advances paper for those details.

Key Findings

  • In obese mice, TOFA raised energy expenditure by up to 18% without increased activity or higher body temperature.
  • Mice improved blood sugar control, lowered harmful blood fats and reduced liver fat (mouse data only).
  • Fat loss occurred without a significant reduction in lean muscle mass; muscle strength or function was not reported in the excerpt.
  • Combining TOFA with GLP-1 medications gave greater benefits than either alone in mice.
  • Safety and effectiveness in humans are not established; no lifespan results were reported.

Methodology

This is a university press release republished by ScienceDaily, summarizing a mouse study in Science Advances from UC Berkeley. The source is credible, but the excerpt omits sample size, dose, duration and mechanism details. Evidence is preclinical, covering metabolic mechanism and body composition, not human outcomes or lifespan.

Study Limitations

Only mice were studied, and the excerpt gives no group sizes, dosing, duration, or molecular mechanism. Lean mass was reported, but not strength or function, and no safety or toxicity data or lifespan data are described. Verify details in the Science Advances paper.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: